OMX Helsinki — S&P 500 — DAX — NASDAQ 100 — STOXX 600 — EUR/USD — EUR/SEK — BTC/USD — ETH/USD — Euribor 3M — Euribor 12M —
Slush

Slush

Startups and entrepreneurship 29,200 subscribers

Florian Brand (Atai Life Sciences): Psychedelics – The New Psychiatric Frontier | Slush 2021

06.12.2021 2,076 views
Published: 06.12.2021 Category: Startups and entrepreneurship Views: 2,076

Episode details

Episode description

Every once in a while, interest in psychedelics as a way to treat mental health disorders is evoked. There’s an extensive body of scientific research dedicated to studying psychedelics and their effect on mental health, yet suspicion towards them is deeply ingrained in collective memory. The path to patients is hard to find, both due to general scepticism as well as regulatory challenges. Atai Life Sciences is a mental health unicorn thriving in an extremely difficult environment. Now, its Co-Founder and CEO Florian Brand will walk us through the state of research, path to patients and navigating the regulatory landscape.

Open the AI assistant chat. The chat loads only when you open it.